The clinical trial results indicate that SaNOtize’s Nitric Oxide Nasal Spray (NONS) represents a safe and effective antiviral treatment that could prevent the transmission of COVID-19 shorten its course, and reduce the severity of symptoms and damage in those already infected, was announced today.
Vancouver-based SaNOtize Research & Development Corp issued a press release stating a Phase 2 trial found early treatment with NONS for COVID-19 significantly reduced the level of SARS-CoV-2 coronavirus, including in patients with high viral loads.
Nitric Oxide Nasal Spray Found Effective Against SARS-CoV-2
March to November 2020 Saw Drop in COVID-19 Mortality at Nursing Homes
Adjusted mortality rates significantly declined from high of 20.9 percent in early April to 11.2 percent in early November
Mortality Up With Surgery Within Six Weeks of SARS-CoV-2 Infection
When possible, delay of at least seven weeks after SARS-CoV-2 diagnosis should be sought; however, mortality rates higher for those with ongoing symptoms
COVID-19 Impacting Caregivers of Children With Cancer
Changes to medical care, financial disruptions, and emotional distress reported
Statin Use Tied to Better COVID-19 Survival
Findings show 53 percent increased survival among patients using statins before hospitalization
COVID-19 Vaccines Given to Americans Top 100 Million
As of Monday, more than 37.4 million Americans are now fully vaccinated, 11.3 percent of the total population
AstraZeneca Says Its COVID-19 Vaccine Is Safe, Despite Reports of Deadly Clots
The AstraZeneca vaccine, developed with researchers from Oxford University, has been heavily used in Britain